Skip to main content
OpenTrials
Completed

NCT Number: NCT02277145

A Study on Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells

Radiation therapy is one of the main means for treating malignant tumor, during which radioactive lung injury is inevitable. Currently there is nearly no effective clinical treatment for late post-radiotherapy pulmonary fibrosis. This study intends to carry out an open, single-center, non-randomized phase I clinical trial. During the treatment, the local lesions will be fully lavaged, and then clinical grade umbilical cord mesenchymal stem cells (MSCs) will be injected directly into the lesion by fiberoptic bronchoscopy. After six-month observation, the investigators will initially evaluate the safety and effectiveness of the treatment by measuring two key indicators-the CT density histogram and the patients' self-evaluation, and one secondary indicator-the changes of TGF-β1 contents, both before and after the treatment. Meanwhile, the investigators will make a preliminary discuss about the possible immunomodulatory effects of the umbilical cord MSCs.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Post-radiotherapy Pulmonary Fibrosis

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

First Affiliated Hospital of the Third Military University, PLA (Southwest Hospital)

Chongqing, Chongqing Municipality, 400038, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, 18-70 years old.
  • Subjects with a clear history of malignancy.
  • Subjects with a clear history of chest radiation therapy at least 3 months earlier.
  • Subjects diagnosed as chronic phase of radiation-induced pneumonitis or radiation-induced pulmonary fibrosis stage (see Annex 3 for diagnosis).
  • Subjects signed informed consent.

Exclusion criteria

  • Women of childbearing age at the stage of pregnancy or lactation, or those without taking effective contraceptive measures.
  • Subjects with syphilis or HIV positive antibody.
  • Subjects with infection aggravated within the past month.
  • Subjects suffering from any of the following pulmonary diseases: active tuberculosis, pulmonary embolism, pneumothorax, multiple huge bullae, uncontrolled asthma, severe pneumonia, acute exacerbation of chronic bronchitis, AECOPD, severe and / or extremely severe COPD, etc..
  • Subjects suffering from other serious diseases, such as myocardial infarction, unstable angina, cirrhosis, and acute glomerulonephritis.
  • Subjects with progression-free survival (PFS) less than 0.5 years or Karnofsky performance scores less than 60 points.
  • Subjects with leukopenia (WBC less than 4x109 / L) or agranulocytosis (WBC less than 1.5x109 / L or neutrophils less than 0.5x109 / L) caused by any reason.
  • Subjects with severe renal impairment, serum creatinine> 1.5 times the upper limit of normal.
  • Subjects with liver disease or liver damage: ALT, AST, total bilirubin> 2 times the upper limit of normal
  • Subjects with a history of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders.
  • Subjects with severe arrhythmias (such as ventricular tachycardia, frequent superventricular tachycardia, atrial fibrillation, and atrial flutter, etc.) or cardiac degree II or above conduction abnormalities displayed via 12-lead ECG.
  • Subjects with a history of alcohol or illicit drug abuse.
  • Subjects accepted by any other clinical trials within 3 months before the enrollment
  • Subjects with poor compliance, difficult to complete the study.
  • Any other conditions that might increase the risk of subjects or interfere with the clinical trial.

Treatment and study plan

clinical grade umbilical cord mesenchymal stem cells

Biological

10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions

Primary outcomes

  1. Composite indicators, including quantitative analysis of CT density histograms, self-evaluation and changes of TGF-β1 content

    Time frame: 6 months

    Different proportions will be assigned to the three indicators. The overall curative effect can be judged with scores ranging from 0 to100. Specific proportions are as follows: full scores of 50 points for image changes, 25 for self-efficacy evaluation and 25 for TGF-β1 content changes. The image changes can be classified into four levels: significant control, improved, stable, and progressive; the self-efficacy evaluation can also be classified into four levels: effective, improved, stable and invalid; the changes of TGF-β1 content will be classified into three levels: improved, stable, and progressive. The four levels will be scored on the ratio of 5:4:3:1, the three levels will be scored on the ratio of 5:3:1.

  2. Safety Evaluation

    Time frame: 6 months

    Clinical adverse events evaluated as definitely/ probably/possibly concerned with stem cell therapy in this trial and abnormal results of laboratory tests or other special examinations will be observed and recorded in detail.

Secondary outcomes

  1. Clinical Indicator 1: change in blood gas analysis

    Time frame: 3-6 months

  2. Clinical Indicator 2: change in pulmonary function analysis

    Time frame: 3-6 months

  3. Clinical Indicator 3: 6-minute walk test distance

    Time frame: 3-6 months

  4. Clinical Indicator 4: change in MRC chronic dyspnea scale

    Time frame: 3-6 months

  5. Clinical Indicator 5: change in St. George's Respiratory Questionnaire (SGRQ) scale

    Time frame: 3-6 months

  6. Immunological Indicator in serum 1: T lymphocyte counts in peripheral blood

    Time frame: 3-6 months

    Cellular immunological indicator: T lymphocyte counts in peripheral blood measured in serum

  7. Immunological Indicator in serum 2: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2)

    Time frame: 3-6 months

    Cellular immunological indicator: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2) measured in serum

  8. Immunological Indicator in serum 3: concent of immunoglobulin

    Time frame: 3-6 months

    Humoral immunological indicator: concent of immunoglobulin measured in serum

  9. Immunological Indicator in serum 4: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc)

    Time frame: 3-6 months

    Humoral immunological indicator: expression levels of various cytokines in serum (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc) measured in serum

  10. Immunological Indicator in serum 5: subtype analysis and phagocytic activity analysis of macrophage

    Time frame: 3-6 months

    Macrophage-related polarization indicator: subtype analysis and phagocytic activity of macrophage measured in serum

  11. Immunological Indicator in serum 6: expression levels of IL-12, IL-10

    Time frame: 3-6 months

    Macrophage- related polarization indicators: expression levels of IL-12, IL-10 measured in serum

  12. Immunological Indicator in lavage fluid 1: T lymphocyte counts in peripheral blood

    Time frame: 6 months

    Cellular immunological indicator: T lymphocyte counts in peripheral blood measured in lavage fluid

  13. Immunological Indicator in lavage fluid 2: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2)

    Time frame: 6 months

    Cellular immunological indicator: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2) measured in lavage fluid

  14. Immunological Indicator in lavage fluid 3: concent of immunoglobulin

    Time frame: 6 months

    Humoral immunological indicator: concent of immunoglobulin measured in lavage fluid

  15. Immunological Indicator in lavage fluid 4: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc)

    Time frame: 6 months

    Humoral immunological indicator: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc) measured in lavage fluid

  16. Immunological Indicator in lavage fluid 5: subtype analysis and phagocytic activity analysis of macrophage

    Time frame: 6 months

    Macrophage-related polarization indicator: subtype analysis and phagocytic activity of macrophage measured in lavage fluid

  17. Immunological Indicator in lavage fluid 6: expression levels of IL-12, IL-10

    Time frame: 6 months

    Macrophage-related polarization indicators: expression levels of IL-12, IL-10 measured in lavage fluid

  18. Inflammatory Indicators: measured by routine blood test including C-reactive protein (CRP)

    Time frame: 3 months

  19. Fibrosis Indicators in serum 1: content of transforming growth factor -α/β (TGF-α/TGF-β)

    Time frame: 3-6 months

    Content of transforming growth factor α/β (TGF-α/TGF-β) measured in serum

  20. Fibrosis Indicators in serum 2: content of hydroxyproline

    Time frame: 3-6 months

    Content of hydroxyproline measured in serum

  21. Fibrosis Indicators in serum 3: content of matrix metalloproteinase 1/7(MMP1/MMP7)

    Time frame: 3-6 months

    Content of matrix metalloproteinase 1/7(MMP1/MMP7) measured in serum

  22. Fibrosis Indicators in lavage fluid 1: content of transforming growth factor -α/β (TGF-α/TGF-β)

    Time frame: 6 months

    Content of transforming growth factor -α/β (TGF-α/TGF-β) measured in lavage fluid

  23. Fibrosis Indicators in lavage fluid 2: content of hydroxyproline

    Time frame: 6 months

    Content of hydroxyproline measured in lavage fluid measured in lavage fluid

  24. Fibrosis Indicators in lavage fluid 3: content of matrix metalloproteinase 1/7(MMP1/MMP7)

    Time frame: 6 months

    Content of matrix metalloproteinase 1/7(MMP1/MMP7) measured in lavage fluid

Sponsors and collaborators

Lead sponsor

Jianwu Dai

Other Gov

Collaborators

  • Southwest Hospital, China

Registry information

Official study title

Phase I Study of Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
Oct 28, 2014
Registry last updated
Jul 24, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.